US-based Neurolief has announced the approval of its neuromodulation device, Relivion, by the Japanese Ministry of Health, Labor and Welfare (MHLW). This approval marks a historic moment for Neurolief and its partner Sawai Pharmaceutical Co., as Relivion becomes the first neuromodulation device approved in Japan for at-home use in the acute treatment of migraine.

Relivion is a novel, non-invasive multi-channel brain neuromodulation technology. It stands out by concurrently stimulating the occipital and trigeminal nerve branches in the head, effectively modulating brain networks associated with debilitating migraine headaches.

The system is complemented by a state-of-the-art patient mobile app and a physician interface featuring cloud-enabled data-tracking capabilities, allowing seamless artificial intelligence (AI) integration and enabling remote patient monitoring.

Marketing efforts for Relivion will be led by Sawai Pharmaceutical Co., which have entered into an exclusive partnership agreement with Neurolief for development and commercialisation of Relivion for migraine and depression indications in Japan.

With the upcoming introduction of the Relivion neuromodulation system in Japan, Sawai aims to elevate the landscape of acute migraine treatment options which is currently limited primarily to drug therapy.